|
Rapamycins are macrocyclic lactones that possess immunosuppressive, antifungal and antitumor properties. The parent compound, rapamycin, is approved as an immunosup-pressive agent for preventing rejection in patients receiving organ transplantation. Rapamycin, also called sirolimus, drug characterized primarily by its ability to suppress the immune system, which led to its use in the prevention of transplant rejection. Rapamycin is produced by the soil bacterium Streptomyces hygroscopicus. The drug’s name comes from Rapa Nui, the indigenous name of Easter Island, where the compound was originally discovered in soil samples in the 1970s. Rapamycin exerts its immunosuppressive effects by inhibiting the activation and proliferation ofT cells. It acts specifically on FK-binding protein 12 (FKBP12), a substance commonly referred to as an immunophilin because it binds to immunosuppressive drugs. A drug used to keep the body from rejecting organ and bone marrow transplants. Rapamycin blocks certain white blood cells that can reject foreign tissues and organs. It also blocks a protein that is involved in cell division. It is a type of antibiotic, a type of immunosuppressant, and a type of serine/threonine kinase inhibitor. Rapamycin is now called sirolimus.
Related Articles -
Rapamycin, 53123-88-9,
|
